TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Thursday morning. The firm issued a hold rating on the stock.

TherapeuticsMD Trading Up 0.3 %

Shares of NASDAQ:TXMD opened at $1.89 on Thursday. The stock has a 50 day moving average of $1.74 and a 200 day moving average of $2.00. TherapeuticsMD has a 12-month low of $1.43 and a 12-month high of $3.96.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.23 million during the quarter.

Hedge Funds Weigh In On TherapeuticsMD

Hedge funds and other institutional investors have recently made changes to their positions in the company. Prosperity Consulting Group LLC bought a new stake in TherapeuticsMD during the first quarter valued at about $56,000. ADAR1 Capital Management LLC purchased a new position in shares of TherapeuticsMD in the fourth quarter worth about $612,000. Finally, Clearline Capital LP raised its stake in shares of TherapeuticsMD by 18.9% in the second quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock worth $1,025,000 after purchasing an additional 101,282 shares during the last quarter. Institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.